Oxford Asset Management’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Oxford Asset Management’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-822	Closed	-$271K	–	1659
2019 Q4	$271K	Buy	+822	New	+$377K	0.01%	1469
2019 Q1	–	Sell	-465	Closed	-$170K	–	2134
2018 Q4	$170K	Buy	465 +259	+126%	+$139K	﹤0.01%	1577
2018 Q3	$137K	Sell	206 -51	-20%	-$36.1K	﹤0.01%	1632
2018 Q2	$223K	Buy	+257	New	+$294K	﹤0.01%	1569

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

FNC

First National Corp Rockland, Massachusetts $527M AUM 12.33% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VFA

Values First Advisors Gray, Tennessee $219M AUM 33.32% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Oxford Asset Management's NBRV Position: Q1 2020 in Review

Oxford Asset Management sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2020, closing a stake of 822 shares — an estimated $271K sold.

Oxford Asset Management first reported a position in NBRV in Q2 2018 and held it in 4 quarters. The position peaked at $271K in Q4 2019. 50 funds tracked by Wall St. Rank hold NBRV as of Q1 2020.

Oxford Asset Management reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 822 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2020, an estimated $271K.
Oxford Asset Management first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q2 2018 and held it in 4 quarters.
Oxford Asset Management's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $271K in Q4 2019.
50 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.